Related Experiment Video

Updated: Dec 13, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A

Hossam Z Mohamed1, Nagwa A Sabri2, Hossam M Zaki1

  • 1Hepatology Department, Kobri El koba Armed Forces Hospital, Cairo, Egypt.

Clinical and Experimental Hepatology
|July 31, 2020
PubMed

Insights

Simvastatin may improve treatment success for chronic hepatitis C (CHC) patients using direct-acting antivirals (DAAs). Adding simvastatin to sofosbuvir/daclatasvir showed a trend towards reduced treatment failure, highlighting statins

Area of Science:

  • Hepatology and Viral Gastroenterology
  • Pharmacology and Drug Development

Background:

  • Chronic hepatitis C (CHC) impacts over 71 million globally, with direct-acting antivirals (DAAs) as primary therapy.
  • Lipid profile alterations are a key consideration in DAA treatment outcomes.
  • Understanding adjunct therapies like statins is crucial for optimizing CHC management.

Purpose of the Study:

  • To evaluate the clinical impact of statins as an adjunct therapy in CHC patients.
  • To assess the effect of simvastatin on sustained virological response (SVR12) and lipid profiles in CHC patients receiving sofosbuvir/daclatasvir (SOF/DAC).

Main Methods:

  • A randomized controlled trial involving 100 treatment-naïve CHC patients.
  • Intervention group received simvastatin 10 mg plus SOF/DAC daily for 12 weeks.
  • Control group received placebo plus SOF/DAC daily for 12 weeks; SVR12, lipid profile, CRP, and fibrosis were assessed.

Main Results:

  • No significant side effects were reported in either group.
  • The simvastatin group showed a trend towards lower SVR failure rate (2%) compared to placebo (10%), though not statistically significant (p > 0.05).
  • Logistic regression identified high baseline CRP, low baseline hemoglobin, and non-statin use as independent predictors of SVR failure (p < 0.05).

Conclusions:

  • Simvastatin may play a beneficial role in enhancing the efficacy of SOF/DAC treatment for CHC.
  • Statins could be an important component for successful CHC treatment outcomes when used with DAAs.
Abstract

Keywords:
chronic hepatitis Csofosbuvir/daclatasvirstatins

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.4K
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.9K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
107
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
133
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
108
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
123
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
439